Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TOCILIZUMAB Cause Intentional dose omission? 75 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 75 reports of Intentional dose omission have been filed in association with TOCILIZUMAB (Tocilizumab-anoh). This represents 0.1% of all adverse event reports for TOCILIZUMAB.

75
Reports of Intentional dose omission with TOCILIZUMAB
0.1%
of all TOCILIZUMAB reports
5
Deaths
15
Hospitalizations

How Dangerous Is Intentional dose omission From TOCILIZUMAB?

Of the 75 reports, 5 (6.7%) resulted in death, 15 (20.0%) required hospitalization, and 3 (4.0%) were considered life-threatening.

Is Intentional dose omission Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TOCILIZUMAB. However, 75 reports have been filed with the FAERS database.

What Other Side Effects Does TOCILIZUMAB Cause?

Drug ineffective (32,342) Rheumatoid arthritis (20,652) Pain (18,384) Off label use (18,256) Arthralgia (15,536) Joint swelling (14,831) Fatigue (13,802) Rash (12,327) Drug intolerance (11,952) Contraindicated product administered (11,547)

What Other Drugs Cause Intentional dose omission?

DUPILUMAB (2,269) CERTOLIZUMAB PEGOL (1,253) ADALIMUMAB (845) TOFACITINIB (845) INFLIXIMAB (815) ABALOPARATIDE (623) ETANERCEPT (615) AMBRISENTAN (595) SODIUM OXYBATE (580) CALCIUM OXYBATE\MAGNESIUM OXYBATE\POTASSIUM OXYBATE\SODIUM OXYBATE (518)

Which TOCILIZUMAB Alternatives Have Lower Intentional dose omission Risk?

TOCILIZUMAB vs TOCILIZUMAB-AAZG TOCILIZUMAB vs TOCOPHEROL TOCILIZUMAB vs TOFACITINIB TOCILIZUMAB vs TOFERSEN TOCILIZUMAB vs TOLNAFTATE

Related Pages

TOCILIZUMAB Full Profile All Intentional dose omission Reports All Drugs Causing Intentional dose omission TOCILIZUMAB Demographics